Consolidated turnover for 2010
Exceptional performance linked to international licensing agreements BioAlliance Pharma SA (Euronext Paris-BIO), a company dedicated to the supportive care and […]
Full-year financial results for 2010
The company posts a profit as a result of an exceptional revenue High potential for further growth Paris, March 3, […]
Q1 2011: achievement of key milestones in BioAlliance Pharma’s clinical development program
Recurring revenue streams reflect the international deployment of Loramyc® BioAlliance Pharma SA (Euronext Paris –BIO), a company dedicated to specialty […]
Q2 2011: BioAlliance Pharma accelerates the progress of its “Orphan oncology products” portfolio and pursues its international partnerships on its “Specialty products”
BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan oncology products, today reported a consolidated […]
Consolidated accounts for the first semester of 2011 and recent significant key events
• Key achievements in the clinical development of orphan oncology products • Strongly reinforced cash position after successful capital increase […]
BioAlliance Pharma reports its consolidated turnover for Q3 And announces progress for Loramyc® commercialization in Italy
BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to specialty and orphan oncology products, today reported a consolidated […]